Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC, together with its CEO Dong Liu and Chief Scientific Officer Shaojiang Deng, announced a resolution of their recent dispute with FibroGen, Inc. regarding Kind Pharmaceuticals’ hypoxia-inducible factor prolyl hydroxylase inhibitortechnology. The parties have agreed to withdraw all pending legal proceedings between them regarding this HIF-PHI technology, without payment by either party. As a result of the settlement, Kind Pharmaceuticals remains free to develop AND017 and other HIF-PHIs in its pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FGEN:
- FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
- FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
- Unusually active option classes on open March 14th
- FibroGen appoints Deyaa Adib as CMO
- FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
